ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.
Guardado en:
Autores principales: | Geneviève Deblois, Harvey W. Smith, Ingrid S. Tam, Simon-Pierre Gravel, Maxime Caron, Paul Savage, David P. Labbé, Louis R. Bégin, Michel L. Tremblay, Morag Park, Guillaume Bourque, Julie St-Pierre, William J. Muller, Vincent Giguère |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a807b71593d5451987bf6593688f61a3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The asymmetric binding of PGC-1α to the ERRα and ERRγ nuclear receptor homodimers involves a similar recognition mechanism.
por: Maria Takacs, et al.
Publicado: (2013) -
Estrogen-related receptor alpha (ERRα) is a key regulator of intestinal homeostasis and protects against colitis
por: Allan Tran, et al.
Publicado: (2021) -
Clinical data mining reveals analgesic effects of lapatinib in cancer patients
por: Shuo Zhou, et al.
Publicado: (2021) -
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
por: J Robert McCorkle, et al.
Publicado: (2021) -
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012)